SG16

Overview

SG16 (Keap1-Nrf2-IN-28) is an orally active Keap1 - Nrf2 inhibitor. SG16 disrupts the binding of Keap1 to Nrf2, promotes the nuclear translocation of Nrf2, upregulates the downstream antioxidant proteins HO-1 and GCLM, and simultaneously inhibits microglial overactivation and proinflammatory cytokine secretion. By activating the Nrf2 pathway, SG16 can be used in studies on oxidative stress, ischemic stroke and acute liver injury.

Application

Products | Products > Disease Areas > Oxidative Stress and Inflammation | Products > Disease Areas > Ischemic Stroke | Products > Disease Areas > Liver Injury | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Cerebrovascular Disease | Products > Disease Areas > Liver Disease | Products > Signaling Pathways > NF-κB | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Keap1-Nrf2

Product Information

• Catalog No.: HY-172598
• CAS No.: 3075750-60-3
• Molecular Formula: C22H16FNO5S
• Molecular Weight: 425.43
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source